Bristol-Myers Squibb Company (BMY) — Fair Value Analysis

Base-case fair value (P50): $56.12 · Current price: $57.00 · Verdict: Fairly Valued

The Verdict on BMY

Bristol Myers Squibb (BMY) is currently deemed Fairly Valued based on our extensive Monte Carlo simulations, which pinpoint a median fair value (P50) of $56.12. This assessment implies that BMY’s current trading price of $57.00 is largely consistent with its intrinsic value derived from thousands of forward-looking scenarios. The observed -1.5% suggests a slight lean below the median P50, yet it falls well within the margin defining a "fairly valued" asset, indicating that the stock is neither significantly overvalued nor undervalued at this juncture. This neutral outlook is a key takeaway from our probabilistic modeling.

How BMY stacks up against Healthcare

When evaluating BMY within its competitive landscape, our analysis assigns it an "average" quality tier compared to other companies in the Healthcare sector. This "average" operational and financial health assessment aligns with the Fairly Valued verdict. A stock trading at $57.00 and approximating its median fair value of $56.12, despite the slight -1.5%, is often characteristic of a company with a stable, albeit not exceptional, fundamental profile within its industry. This positioning suggests BMY is efficiently priced relative to its peers given its inherent strengths and challenges.

What this means for investors

For investors considering BMY, the Fairly Valued status, coupled with an "average" quality tier, implies that the current price of $57.00 reflects a balanced risk-reward proposition. The -1.5% indicates minimal immediate arbitrage opportunity based on valuation alone. While significant valuation-driven upside may be limited, BMY’s stability at its $56.12 fair value could appeal to those seeking a steady holding rather than rapid capital appreciation. To gain deeper insight into BMY's potential outcomes, including detailed bear-case and bull-case distributions, and to track its evolving fair value as new data emerges, sign up for a free FairCurve account.